

[摘要] 目的 探究玻璃酸鈉聯合重組牛堿性成纖維細胞生長因子(r-bFGF)滴眼液治療142例干眼癥并角膜上皮損傷的臨床效果。方法 整群選取2014年2月—2016年2月于該院診治的284例(284只眼)干眼癥并角膜上皮損傷患者采用隨機數字表法均分為兩組,每組142例。對照組給予玻璃酸鈉滴眼液治療,觀察組給予玻璃酸鈉聯合r-bFGF滴眼液治療。比較兩組患者裂隙燈下淚膜破裂時間(BUT)、淚液分泌試驗(SIt) 情況;比較兩組患者臨床療效。結果 治療后觀察組SIt(7.53±0.89)mm、BUT(6.27±1.23)s顯著高于治療前(4.46±0.94)mm、(4.06±0.82)s及對照組(6.03±0.72)mm、(5.24±1.11)s(P<0.05)。治療后觀察組總有效率為94.37%較對照組71.83%顯著較高,差異有統計學意義(P<0.05)。結論 玻璃酸鈉聯合r-bFGF滴眼液治療干眼癥并角膜上皮損傷患者可顯著延長BUT、改善淚液分泌情況,其臨床療效尤佳。
[關鍵詞] 玻璃酸鈉;r-bFGF滴眼液;干眼癥
[中圖分類號] R777 [文獻標識碼] A [文章編號] 1674-0742(2016)10(b)-0130-03
[Abstract] Objective Study of sodium hyaluronate and recombinant bovine basic fibroblast growth factor (bFGF) eyedrops in the treatment of 142 cases of dry eye and corneal epithelial injury and the clinical effect of. Methods Group selection from February 2014 to February 2016 in our hospital for treatment of 284(284 eyes) dry eye and corneal epithelial injury in patients with the random number table were divided randomly into two groups,Each group of 142 cases. The control group was given Sodium Hyaluronate Eye Drops treatment, the observation group was treated with sodium hyaluronate combined with r-bFGF eye drops. Compared two groups of patients with slit lamp tear break-up time (BUT), tear secretion test (SIt), compared two groups of patients with clinical curative effect. Results After treatment, the observation group SIt (7.53 ± 0.89) mm, BUT (6.27 ± 1.23) s was significantly higher than before treatment (4.46±0.94) mm, (4.06 ± 0.82) s and control group (6.03±0.72) mm,(5.24±1.11) s (P < 0.05). After treatment, the total effective rate of the observation group was 94.37% compared with the control group (71.83%), the difference was statistically significant (P < 0.05).Conclusion Glass acid sodium combined with bFGF eye drops in treatment of dry eye and corneal epithelial injury patients can be significantly prolonged break-up time (but), improving the tear secretion and its clinical effect is a plus.
[Key words] Sodium hyaluronate; r-bFGF eye drops; Dry eye
干眼癥屬于一種因淚液的質、量和動力學異常造成的淚膜穩定性下降而引起眼部不適的眼科疾病[1]。穩定的淚膜覆蓋在眼球角膜的上方,因而重度干眼癥患者易出現角膜上皮損傷。臨床上,干眼癥患者以抗炎、封閉淚道及人工眼淚滴眼為常規治療措施[2]。整群選擇2014年2月—2016年2月于該院診治的284例(284只眼)干眼癥并角膜上皮損傷患者作為研究對象,給予玻璃酸鈉聯合重組r-bFGF滴眼液治療,并觀察其臨床效果,現報道如下。
1 資料與方法
1.1 一般資料
整群選擇于該院診治的干眼癥并角膜上皮損傷患者284例(284只眼)。所有患者均只有一只患眼,均符合劉祖國等制定的《干眼的診斷與治療規范》[3]中的干眼癥診斷標準?!?br>